Sleep Apnea drugs in development by stages, target, MoA, RoA, molecule type and key players, 2023

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued products.

GlobalData tracks 36 drugs in development for Sleep Apnea by 23 companies/universities/institutes. The top development phase for Sleep Apnea is phase ii with 17 drugs in that stage. The Sleep Apnea pipeline has 30 drugs in development by companies and six by universities/ institutes. Some of the companies in the Sleep Apnea pipeline products market are: Shionogi-Apnimed Sleep Science, Brigham and Women’s Hospital and Apnimed.

The key targets in the Sleep Apnea pipeline products market include Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2), Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2), and Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1).

The key mechanisms of action in the Sleep Apnea pipeline product include Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Inhibitor with six drugs in Phase III. The Sleep Apnea pipeline products include six routes of administration with the top ROA being Oral and four key molecule types in the Sleep Apnea pipeline products market including Small Molecule, and Synthetic Peptide.

Sleep Apnea overview

Sleep apnea, a prevalent condition, involves the recurrent interruption and resumption of breathing during sleep. Two main types exist, obstructive and central sleep apnea. Obstructive sleep apnea occurs when the upper airway is frequently blocked, diminishing or halting airflow. Common risk factors include obesity, enlarged tonsils, and hormonal changes. Central sleep apnea results from the brain’s failure to send necessary signals for breathing. Health conditions affecting the brain’s control over airway and chest muscles contribute to this type. Diagnosis involves a sleep study, with treatments including continuous positive air pressure (CPAP) machines and lifestyle adjustments. Surgical intervention may be considered if initial treatments prove ineffective. Untreated sleep apnea can lead to cognitive difficulties and serious health issues.

For a complete picture of Sleep Apnea’s pipeline drug market, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.